Pharmaceutical composition containing clarithromycin and sudapyridine

The invention belongs to the technical field of medicines, particularly relates to a pharmaceutical composition containing clarithromycin and sudapyridine, and aims to solve the technical problems that medicines for inhibiting mycobacterium abscessus are limited in selection, long in treatment cycle, easy to relapse and resistant to clinically common antibiotics. According to the pharmaceutical composition, the mycobacterium abscessus is inhibited by combining the clarithromycin and the sudapyridine, the sudapyridine has relatively good activity for inhibiting the mycobacterium abscessus, and the clarithromycin has relatively good safety and has a relatively good effect of resisting the activity of the mycobacterium abscessus; according to the pharmaceutical composition, the blood concentration of sudapyridine in tissues can be increased within 16 hours through combined use of clarithromycin and sudapyridine, and a drug combination scheme capable of better inhibiting the activity of the mycobacterium abscessu